These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 17419828)

  • 1. Immunomodulatory treatment of multiple sclerosis in Norway.
    Torkildsen Ø; Grytten N; Myhr KM
    Acta Neurol Scand Suppl; 2007; 187():46-50. PubMed ID: 17419828
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Variation of serum uric acid levels in multiple sclerosis during relapses and immunomodulatory treatment.
    Guerrero AL; Martín-Polo J; Laherrán E; Gutiérrez F; Iglesias F; Tejero MA; Rodríguez-Gallego M; Alcázar C
    Eur J Neurol; 2008 Apr; 15(4):394-7. PubMed ID: 18312403
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Disease-modifying drugs for the early treatment of multiple sclerosis.
    Flachenecker P
    Expert Rev Neurother; 2004 May; 4(3):455-63. PubMed ID: 15853542
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative studies of glatiramer acetate and interferon beta.
    Goodin D
    Int MS J; 2008 Jun; 15(2):39-41. PubMed ID: 18782497
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A practical approach to immunomodulatory therapy for multiple sclerosis.
    Burks JS
    Phys Med Rehabil Clin N Am; 2005 May; 16(2):449-66, ix. PubMed ID: 15893681
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The technology of treatment of multiple sclerosis with long-term immunomodulating drugs (disease modifying drugs--DMD)--beta-interferons and glatiramer-acetate].
    Federal service on surveillance in healthcare and social development (Roszdravnadzor)
    Zh Nevrol Psikhiatr Im S S Korsakova; 2011; 111(2 Pt 2):86-92. PubMed ID: 21916162
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multiple sclerosis in Vest-Agder County, Norway.
    Vatne A; Mygland A; Ljøstad U
    Acta Neurol Scand; 2011 Jun; 123(6):396-9. PubMed ID: 21492097
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The therapy of multiple sclerosis with immune-modulating or immunosuppressive drug. A critical evaluation based upon evidence based parameters and published systematic reviews.
    Clerico M; Rivoiro C; Contessa G; Viglietti D; Durelli L
    Clin Neurol Neurosurg; 2008 Nov; 110(9):878-85. PubMed ID: 18164542
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The UK Risk-Sharing Scheme for interferon-beta and glatiramer acetate in multiple sclerosis. Outcome of the year-6 analysis.
    Duddy M; Palace J
    Pract Neurol; 2016 Feb; 16(1):4-6. PubMed ID: 26430247
    [No Abstract]   [Full Text] [Related]  

  • 10. [Immunomodulatory treatments for multiple sclerosis: lessons from direct comparative studies].
    Ouallet JC
    Rev Neurol (Paris); 2010 Jan; 166(1):21-31. PubMed ID: 19596382
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Pharmacological treatment of multiple sclerosis].
    Myhr KM
    Tidsskr Nor Laegeforen; 2010 Mar; 130(5):490-2. PubMed ID: 20224616
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term results of immunomodulatory treatment in children and adolescents with multiple sclerosis: the Italian experience.
    Ghezzi A; Amato MP; Annovazzi P; Capobianco M; Gallo P; La Mantia L; Marrosu MG; Martinelli V; Milani N; Moiola L; Patti F; Pozzilli C; Trojano M; Zaffaroni M; Comi G;
    Neurol Sci; 2009 Jun; 30(3):193-9. PubMed ID: 19387545
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Diagnosis and treatment of multiple sclerosis. Update, 2003].
    Jarius S; Hohlfeld R; Voltz R
    MMW Fortschr Med; 2003 May; 145 Suppl 2():88-91, 93, 95. PubMed ID: 14579493
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fcγ receptors in Norwegian multiple sclerosis patients and healthy controls.
    Gavasso S; Torkildsen Ø; Marøy TH; Ulvestad E; Myhr KM; Vedeler CA
    Acta Neurol Scand Suppl; 2012; (195):84-9. PubMed ID: 23278662
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Pathogenesis and treatment of multiple sclerosis (state of the art in 2000)].
    Zavalishin IA; Zhuchenko TD; Peresedova AV
    Vestn Ross Akad Med Nauk; 2001; (7):18-22. PubMed ID: 11523422
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics and pharmacodynamics of the interferon-betas, glatiramer acetate, and mitoxantrone in multiple sclerosis.
    Neuhaus O; Kieseier BC; Hartung HP
    J Neurol Sci; 2007 Aug; 259(1-2):27-37. PubMed ID: 17391705
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adherence to Disease Modifying Drugs among Patients with Multiple Sclerosis in Germany: A Retrospective Cohort Study.
    Hansen K; Schüssel K; Kieble M; Werning J; Schulz M; Friis R; Pöhlau D; Schmitz N; Kugler J
    PLoS One; 2015; 10(7):e0133279. PubMed ID: 26214805
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current disease-modifying therapies in multiple sclerosis.
    Kieseier BC; Hartung HP
    Semin Neurol; 2003 Jun; 23(2):133-46. PubMed ID: 12894379
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Persistence and adherence to disease modifying drugs among patients with multiple sclerosis.
    Reynolds MW; Stephen R; Seaman C; Rajagopalan K
    Curr Med Res Opin; 2010 Mar; 26(3):663-74. PubMed ID: 20070144
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Editorial: the pitfalls of combination therapy.
    Vermersch P
    Int MS J; 2006 Nov; 13(3):75-6. PubMed ID: 17101074
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.